School of Chemistry and Chemical Engineering , Southeast University , Nanjing 210089 , PR China.
Department of Respiratory Medicine , The Affiliated Zhongda Hospital of Southeast University , Nanjing 210009 , PR China.
ACS Appl Mater Interfaces. 2018 Sep 19;10(37):30930-30935. doi: 10.1021/acsami.8b12800. Epub 2018 Sep 7.
Herein, a biocompatible 2D metal-organic frameworks (Cu-TCPP(Fe)) based on TCPP(M) (TCPP = tetrakis (4-carboxyphenyl) porphyrin, M = Fe) and copper ion were synthesized as a novel drug carrier. Sequentially, the cisplatin was loaded on the merge of carboxyl-rich Cu-TCPP(Fe) through forming favorable carboxyl-drug interactions. The prepared Pt/Cu-TCPP(Fe) showed highly enhanced cytotoxicity than that of free cisplatin in human pulmonary carcinoma A549 cells, whereas inverse inhibitory effects were observed in human normal BEAS-2B cells. Further, the mechanism of action about the desirable results was also elaborated. Our study highlighted the potential synergies between the nanocarrier and the anticancer drugs.
在此，我们合成了一种基于 TCPP（M）（TCPP = 四（4-羧基苯基）卟啉，M = Fe）和铜离子的生物相容性 2D 金属有机骨架（Cu-TCPP(Fe)）作为新型药物载体。随后，顺铂通过形成有利的羧基-药物相互作用负载在富含羧基的 Cu-TCPP(Fe) 上。与游离顺铂相比，制备的 Pt/Cu-TCPP(Fe) 在人肺癌 A549 细胞中表现出更高的细胞毒性，而在人正常 BEAS-2B 细胞中则观察到相反的抑制作用。此外，还阐述了产生理想结果的作用机制。我们的研究强调了纳米载体和抗癌药物之间的潜在协同作用。
